DALLAS, May 7, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. (Nasdaq:KERX). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.microstockprofit.com/ads/KERX
Keryx Biopharmaceuticals Inc. (KERX) engages in the acquisition, development and commercialization of drug therapies for the treatment of renal disease and cancer. The Company's novel, oral anti-cancer agent called KRX-0401 (perifosine) is developed to inhibit cell growth and cell transformation. KRX-0401 has cleared Phase I clinic trials for safety and efficacy. KRX-0401 is currently in Phase II clinical trials to determine efficacy for multiple tumor types, and Phase III for the efficacy to treat multiple myeloma. The Company seeks strategic relationships to develop drug candidates, including evaluating compounds for acquisition or licensing.
Message Board Search for KERX: http://www.boardcentral.com/boards/KERX
In the report, the analyst notes:
"KRX-0401 (perifosine) is the Company's lead oral anti-cancer agent developed to modulate important signal transduction pathways, including the JNK and MAPK pathways. JNK and MAPK are identified as the pathways associated with the growth, differentiation, death and survival of human cells. KRX-0401 modulates the Akt pathway, which is believed to be the pathway for the development of most cancers. The Company has evidence that these pathways are activated in tumors that have historically resisted traditional anticancer therapies. The Company's challenge is to inhibit this pathway without excessive toxicity to the patient.
"Recent media coverage of the stock and its leading drug candidate has recently been accelerating as perifosine nears completion of the FDA process and further demonstrates efficacy, safety and potential to treat other conditions.
"The market potential for perifosine and like drugs is estimated to reach more than $10 billion, worldwide, with potential revenue from commercialization of the drug and market capitalization implications of the Company raised substantially if perifosine clears the FDA."
To read the entire report visit: www.microstockprofit.com/ads/KERX
See what investors are saying about KERX at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.